1. Publication
- Title: Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial
- Acronym: 4D
- Year & Journal: Intensive Care Medicine, epublished October 29, 2025 (print: 2025;51(12):2305-2317)
- Citation: Godet T, Louis C, Rieu B, et al; 4D study group. Intensive Care Med. 2025;51(12):2305-2317. doi:10.1007/s00134-025-08135-1
2. Context & Rationale
Background: Hyperactive delirium may require high-dose sedation or intubation for safety. Antipsychotics (haloperidol) are of limited effectiveness and raise safety concerns. Dexmedetomidine's role specifically in non-intubated agitated-delirium patients remained uncertain.
Research Question/Hypothesis: In non-intubated ICU adults with hyperactive delirium, does dexmedetomidine improve a joint composite of agitation duration, delirium duration, or need for intubation/deep sedation vs placebo?
3. Design & Methods
- Study Type: Multicenter, double-blind, placebo-controlled, investigator-initiated RCT
- Setting & Centers: 9 ICUs, France; enrolled Dec 2017 – Feb 2022
- Population: Non-intubated adults with hyperactive delirium
- Intervention: Continuous IV dexmedetomidine, ≥36h, titrated to light cooperative sedation
- Comparator: Placebo infusion
- Randomization: 151 patients in final analysis
- Blinding: Double-blind
- Statistical Power & Follow-Up: Joint modeling primary outcome (agitation duration, delirium duration, intubation/deep sedation). Stopped early for efficacy at interim analysis.
4. Key Results
Outcome | Dexmedetomidine | Placebo | Effect Size | 95% CI | p-value | Notes |
Joint primary outcome | Favorable | — | Median diff −30 pts | −49 to −12 | 0.001 | Significant benefit |
Agitation duration | Shorter | — | — | — | — | Main driver of benefit |
Delirium duration, need for MV | Similar | — | — | — | — | Not different between groups |
Rescue psychotropic use | Less | — | — | — | — | — |
Adverse events, LOS, mortality | No increase | — | — | — | — | No safety penalty |
5. Internal Validity Assessment
- Randomization & Allocation: Multicenter, double-blind; concealment mechanics not fully detailed.
- Protocol Adherence & Separation: Escalation to deep sedation/MV per clinician judgment in both arms.
- Blinding & Detection Bias: Full double-blind — strong protection against bias.
- Missing Data: 17 withdrew post-randomization (consent-related, per French law); minor attrition.
- Overall Internal Validity Conclusion: Strong — stopped early for efficacy at a preplanned interim analysis, double-blind design, clear statistically significant joint-outcome result.
6. External Validity Assessment
French, 9-ICU, non-intubated hyperactive-delirium population — relevant, though single-country, and specifically the non-intubated (not general ICU) subgroup.
7. Strengths & Limitations
Strengths: Double-blind, stopped early for efficacy, addresses a genuinely difficult clinical population (agitated, non-intubated) where options are limited.
Limitations: Single-country; delirium duration and MV need themselves were not significantly different — benefit driven specifically by agitation control.
8. Interpretation & Practice Impact
Supports dexmedetomidine as an effective, safe option to control agitation in non-intubated hyperactive delirium, reducing rescue-medication use without increasing intubation, LOS, or mortality — though it does not appear to shorten delirium itself.
9. Controversies & Subsequent Evidence
Independent commentary (Chacko's blog) confirms benefit was specifically driven by reduced agitation duration, not delirium duration or MV avoidance — an important outcome-specific nuance for clinical application.
10. Summary & Executive Takeaway
Summary: 4D, stopped early for efficacy, randomized 151 non-intubated hyperactive-delirium patients to dexmedetomidine or placebo. The joint primary outcome significantly favored dexmedetomidine (P=0.001), driven by shorter agitation duration; delirium duration and MV need were unchanged; no safety penalty.
Overall Takeaway: Dexmedetomidine effectively and safely controls agitation in non-intubated hyperactive delirium without shortening delirium itself — a targeted, evidence-based option for this difficult population.
11. Bibliography
- Louis C, Godet T, et al. 4D trial protocol. Trials. 2018.